Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
54
LNTH Quote, Financials, Valuation and Earnings
Last price:
$66.71
Seasonality move
:
14.37%
Day range:
$66.10 - $67.74
52-week range:
$47.25 - $111.29
Dividend yield:
0%
P/E ratio:
27.94x
P/S ratio:
3.04x
P/B ratio:
3.94x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
-26.9%
Market cap:
$4.4B
Revenue:
$1.5B
EPS (TTM):
$2.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$364.5M | $1.27 | -5.55% | -29.39% | $82.43 |
|
CYTK
Cytokinetics, Inc.
|
$6M | -$1.57 | -70.66% | -8.84% | $86.56 |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$37.8M | -$0.28 | 50.99% | -69.07% | $22.25 |
|
IART
Integra LifeSciences Holdings Corp.
|
$414.3M | $0.43 | -2.94% | 217.65% | $15.50 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.5% | -35.2% | $8.35 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$235.8M | -$0.34 | -2.02% | -4.07% | $24.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$66.53 | $82.43 | $4.4B | 27.94x | $0.00 | 0% | 3.04x |
|
CYTK
Cytokinetics, Inc.
|
$63.29 | $86.56 | $7.7B | -- | $0.00 | 0% | 86.36x |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$9.63 | $22.25 | $988.8M | -- | $0.00 | 0% | 7.39x |
|
IART
Integra LifeSciences Holdings Corp.
|
$12.59 | $15.50 | $980.7M | 70.14x | $0.00 | 0% | 0.59x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.82 | $8.35 | $1.1B | -- | $0.00 | 0% | 3.73x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$22.62 | $24.81 | $1.5B | -- | $0.00 | 0% | 1.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
35.63% | -1.491 | 18.22% | 2.30x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.410 | 17.83% | 6.81x |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.64% | 0.642 | 0.4% | 8.29x |
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | 0.130 | 179.84% | 1.47x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.243 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$222.4M | $43.6M | 9.52% | 14.66% | 11.36% | $94.7M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$35.3M | -$24.3M | -30.8% | -30.98% | -60.94% | -$5.8M |
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Lantheus Holdings, Inc. vs. Competitors
-
Which has Higher Returns LNTH or CYTK?
Cytokinetics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -15814.98%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About LNTH or CYTK?
Lantheus Holdings, Inc. has a consensus price target of $82.43, signalling upside risk potential of 23.9%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $86.56 which suggests that it could grow by 36.76%. Given that Cytokinetics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Cytokinetics, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 CYTKCytokinetics, Inc.10 3 0 -
Is LNTH or CYTK More Risky?
Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.
-
Which is a Better Dividend Stock LNTH or CYTK?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or CYTK?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 27.94x while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.04x versus 86.36x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.04x 27.94x $384M $27.8M CYTKCytokinetics, Inc.86.36x -- $1.9M -$306.2M
-
Which has Higher Returns LNTH or DAWN?
Day One Biopharmaceuticals, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -49.57%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M -
What do Analysts Say About LNTH or DAWN?
Lantheus Holdings, Inc. has a consensus price target of $82.43, signalling upside risk potential of 23.9%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $22.25 which suggests that it could grow by 131.05%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 DAWNDay One Biopharmaceuticals, Inc.5 1 0 -
Is LNTH or DAWN More Risky?
Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LNTH or DAWN?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or DAWN?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 27.94x while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.04x versus 7.39x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.04x 27.94x $384M $27.8M DAWNDay One Biopharmaceuticals, Inc.7.39x -- $39.8M -$19.7M
-
Which has Higher Returns LNTH or IART?
Integra LifeSciences Holdings Corp. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -1.34%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B -
What do Analysts Say About LNTH or IART?
Lantheus Holdings, Inc. has a consensus price target of $82.43, signalling upside risk potential of 23.9%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 23.11%. Given that Lantheus Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Lantheus Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 IARTIntegra LifeSciences Holdings Corp.2 4 2 -
Is LNTH or IART More Risky?
Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.
-
Which is a Better Dividend Stock LNTH or IART?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or IART?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 27.94x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.04x versus 0.59x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.04x 27.94x $384M $27.8M IARTIntegra LifeSciences Holdings Corp.0.59x 70.14x $402.1M -$5.4M
-
Which has Higher Returns LNTH or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -135.28%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About LNTH or IOVA?
Lantheus Holdings, Inc. has a consensus price target of $82.43, signalling upside risk potential of 23.9%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.35 which suggests that it could grow by 196.1%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is LNTH or IOVA More Risky?
Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock LNTH or IOVA?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or IOVA?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 27.94x while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.04x versus 3.73x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.04x 27.94x $384M $27.8M IOVAIovance Biotherapeutics, Inc.3.73x -- $67.5M -$91.3M
-
Which has Higher Returns LNTH or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -8.49%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About LNTH or TNDM?
Lantheus Holdings, Inc. has a consensus price target of $82.43, signalling upside risk potential of 23.9%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 9.68%. Given that Lantheus Holdings, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Lantheus Holdings, Inc. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is LNTH or TNDM More Risky?
Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.
-
Which is a Better Dividend Stock LNTH or TNDM?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or TNDM?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 27.94x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.04x versus 1.50x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.04x 27.94x $384M $27.8M TNDMTandem Diabetes Care, Inc.1.50x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
